urea has been researched along with Dysmyelopoietic Syndromes in 3 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) suppress normal hematopoietic activity in part by enabling a pathogenic inflammatory milieu in the bone marrow." | 1.43 | Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia. ( Assal, A; Bachegowda, L; Bartenstein, M; Bhagat, T; Bhattacharyya, S; Boultwood, J; Brown, S; Burgess, LE; Chantry, D; Garrus, J; Giricz, O; Gordon-Mitchell, S; Gross, S; Guha, C; Hogeland, G; Mantzaris, I; Morrone, K; Munson, M; Nwankwo, G; Pellagatti, A; Platanias, L; Pradhan, K; Ramachandra, N; Rizzi, J; Rodriguez, M; Schinke, C; Shahnaz, S; Shastri, A; Steidl, U; Sukrithan, V; Verma, A; Winski, SL; Wollenberg, L; Wright, D; Yu, Y; Zou, Y, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia-Manero, G | 2 |
| Khoury, HJ | 1 |
| Jabbour, E | 1 |
| Lancet, J | 1 |
| Winski, SL | 2 |
| Cable, L | 1 |
| Rush, S | 1 |
| Maloney, L | 1 |
| Hogeland, G | 2 |
| Ptaszynski, M | 1 |
| Calvo, MC | 1 |
| Bohannan, Z | 1 |
| List, A | 1 |
| Kantarjian, H | 1 |
| Komrokji, R | 1 |
| Gañán-Gómez, I | 1 |
| Bohannan, ZS | 1 |
| Bachegowda, L | 1 |
| Morrone, K | 1 |
| Mantzaris, I | 1 |
| Bartenstein, M | 1 |
| Ramachandra, N | 1 |
| Giricz, O | 1 |
| Sukrithan, V | 1 |
| Nwankwo, G | 1 |
| Shahnaz, S | 1 |
| Bhagat, T | 1 |
| Bhattacharyya, S | 1 |
| Assal, A | 1 |
| Shastri, A | 1 |
| Gordon-Mitchell, S | 1 |
| Pellagatti, A | 1 |
| Boultwood, J | 1 |
| Schinke, C | 1 |
| Yu, Y | 1 |
| Guha, C | 1 |
| Rizzi, J | 1 |
| Garrus, J | 1 |
| Brown, S | 1 |
| Wollenberg, L | 1 |
| Wright, D | 1 |
| Munson, M | 1 |
| Rodriguez, M | 1 |
| Gross, S | 1 |
| Chantry, D | 1 |
| Zou, Y | 1 |
| Platanias, L | 1 |
| Burgess, LE | 1 |
| Pradhan, K | 1 |
| Steidl, U | 1 |
| Verma, A | 1 |
1 trial available for urea and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Female; Humans; Indazoles; Male; Middle | 2015 |
2 other studies available for urea and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
p38 MAPK in MDS.
Topics: Gene Expression Regulation; Humans; Indazoles; Myelodysplastic Syndromes; p38 Mitogen-Activated Prot | 2015 |
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Topics: Angiopoietin-1; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; | 2016 |